Literature DB >> 27216901

Update on New and Emerging Treatments for Schizophrenia.

Ganesh Gopalakrishna1, Muaid H Ithman2, John Lauriello2.   

Abstract

Although there has been more than 50 years of development, there remains a great need for better antipsychotic medications. This article looks at the recent advances in treatment of schizophrenia. New hypotheses have been suggested that may replace or complement the dopamine hypotheses. The article explores the different novel drugs that impact some of the key neurotransmitter systems currently. Phosphodiesterase 10A inhibitors and α-7 neuronal nicotinic acetylcholine receptor modulators constitute the majority. The marketing of these medications eventually may result in change about how schizophrenia is treated.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Advances; Antipsychotics; Cognition; Negative symptoms; Schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 27216901     DOI: 10.1016/j.psc.2016.01.005

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  3 in total

1.  Potential of PDE10A Inhibitors as Treatment for Schizophrenia and Other Neurological Disorders.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2018-08-06       Impact factor: 4.345

2.  Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia.

Authors:  Karolina Kauppi; Sara Brin Rosenthal; Min-Tzu Lo; Nilotpal Sanyal; Mian Jiang; Ruben Abagyan; Linda K McEvoy; Ole A Andreassen; Chi-Hua Chen
Journal:  Am J Psychiatry       Date:  2018-03-02       Impact factor: 18.112

3.  Superior effects of quetiapine compared with aripiprazole and iloperidone on MK-801-induced olfactory memory impairment in female mice.

Authors:  Ahmet Mutlu; Oguz Mutlu; Guner Ulak; Furuzan Akar; Havva Kaya; Faruk Erden; Pelin Tanyeri
Journal:  Biomed Rep       Date:  2017-03-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.